 |
|
|
| |
A Next Generation HCV DAA Combination: Potent, Pangenotypic Inhibitors ABT-493 and ABT-530 With High Barriers to Resistance
|
| |
| |
Reported by Jules Levin
AASLD Nov 7-11 Boston 2014
Teresa Ng, Tami Pilot-Mati as, Liangjun Lu, Thomas Reisch, Tanya Dekhtyar, Preethi Krishnan, Jill Beyer, Rakesh Tripathi, Ron Pithawalla, Armen Asatryan, Andrew Campbell, Jens Kort, Christine Collins
AbbVie Inc., North Chicago, Illinois, United States
|
| |
|
|
|
|
|
